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ABSTRACT
Background: Although previous studies have suggested that propofol inhibits 
cancer recurrence and metastasis, the association between anesthetic agents and 
the recurrence of breast cancer has not been clearly investigated. We compared total 
intravenous anesthesia and balanced anesthesia with volatile agents to investigate 
the differences in their effects on recurrence-free survival and overall survival after 
breast cancer surgery. 
Materials and Methods: The electronic medical records of 2,729 patients who 
underwent breast cancer surgery between November 2005 and December 2010 
were retrospectively reviewed to analyze the factors associated with recurrence-
free survival after surgery. Cox proportional hazards models were used to identify the 
risk factors for cancer recurrence and overall mortality after breast cancer surgery.
Results: Data from 2,645 patients were finally analyzed. The recurrence-free 
survival rate in this study was 91.2%. Tumor-node-metastasis staging exhibited the 
strongest association with breast cancer recurrence. However, we were unable to 
identify significant differences between the preventive effects of total intravenous 
anesthesia and those of volatile agents on postoperative breast cancer recurrence 
using Cox regression analyses and propensity score matching. Furthermore, the 
survival probability with regard to postoperative recurrence and mortality showed 
no significant differences among anesthetic agents. 
Conclusions: Our findings suggest that the effects of total intravenous anesthesia 
are comparable with those of volatile agents with regard to postoperative recurrence-
free survival and overall survival in patients with breast cancer.
INTRODUCTION
Breast cancer is the most common malignancy 
and the leading cause of cancer-related death in women. 
Several factors may be related to breast cancer recurrence 
or metastasis, including surgery, stress hormones, 
immune-suppression, acute postoperative pain, and 
opioid analgesics [1–3]. After reports showing that cancer 
outcomes could be altered by the choice of anesthetic 
agent during surgery [4], this field has been emerging as 
an area of interest. An animal study demonstrated that 
opioids, volatile anesthetics, thiopental, and ketamine, 
but not propofol, could inhibit natural killer (NK) cell 
activity and cause cancer metastasis [4]. Preliminary data 
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from an ongoing prospective randomized controlled trial 
for radical cystectomy support these findings; improved 
immune function was found in patients who received 
total intravenous anesthesia (TIVA) during surgery. In 
particular, the patients demonstrated enhanced cell-
mediated immunity [5]. Recently, Forget et al. suggested 
that perioperative ketorolac significantly reduces the 
relapse of breast cancer [6], and that inflammation might 
be the precipitating factor and common denominator in 
early relapses [7]. 
However, several studies have recently questioned 
the influence of the anesthetic agent and technique on 
long-term tumor growth [8, 9]. Moreover, a systematic 
review conducted in 2014 concluded that there is 
insufficient data to make any firm conclusions [10].
Therefore, we conducted the present study to 
compare TIVA and balanced anesthesia with volatile 
agents with regard to their effects on the postoperative 
recurrence-free survival and overall survival of patients 
with breast cancer. 
RESULTS
Study population, demographic data and 
perioperative characteristics 
From November 2005 to December 2010, 2,729 
patients underwent surgery following breast cancer 
diagnosis. Among these patients, 63 cases of multiple 
surgery and 21 cases with unclear anesthetic methods were 
excluded. The remaining 2,645 cases, which included 
2,589 in the balanced anesthesia group (Sevoflurane 
group: 1613, Desflurane group: 664, Isoflurane group: 
271, Enflurane group: 41) and 56 in the TIVA group, were 
analyzed for this study. The mean (standard deviation) 
follow-up duration of our papulation was 70.1 (23.2) 
months. The mean recurrence-free survival duration 
was 67.6 and 74.4 months with volatile agents and 
TIVA, respectively. The corresponding overall survival 
duration was 69.9 and 77.1 months with volatile agents 
and TIVA, respectively. Table 1 presents a comparison of 
characteristics between patients with and patients without 
breast cancer recurrence. There were no significant 
differences in baseline demographic data and anesthetic 
data between the two groups. With regard to the surgical 
factors, the surgery type, tumor-node-metastasis (TNM) 
stage, estrogen and progesterone receptor (ER and PR) 
status, histological type, and chemotherapy use showed 
significant differences between groups.
Association between anesthetic agents and 
cancer recurrence after surgery for breast cancer
Table 2 shows the findings of the Cox regression 
analyses for factors increasing postoperative breast cancer 
recurrence. According to the multivariate Cox regression 
analyses, there was no difference in the recurrence-
free survival between TIVA and balanced anesthesia. 
Recurrence of cancer was significantly related to surgical 
procedure, higher cancer stage, ER-positive cancer cells, 
and implementation of chemotherapy. 
Table 3 describes the sensitivity analysis for our 
primary findings. There were no differences in the 
recurrence after breast cancer surgery between TIVA and 
the volatile anesthetics. Next, in our 1-to-5 propensity 
score-matched analysis, there was also no association 
of TIVA or any of the volatile agents with postoperative 
recurrence. Figure 1 demonstrates the survival probability 
for each anesthetic agent with regard to recurrence-free 
survival after breast cancer surgery. Log-rank tests showed 
no significant differences between agents (P = 0.646).
Association between anesthetic agents and 
overall mortality after surgery for breast cancer
Table 4 details the relationship between each 
anesthetic agent and overall mortality as determined 
by multivariate Cox regression analyses and 1:5 
propensity score matching. None of the anesthetic 
agents demonstrated a significant association. Figure 2 
demonstrates the survival probability for each anesthetic 
agent with regard to postoperative overall survival 
for breast cancer patients. Log-rank tests showed no 
significant differences between agents (P = 0.403).
DISCUSSION
To the best of our knowledge, this is the first study 
to analyses the effects of anesthetics on postoperative 
breast cancer recurrence and overall mortality in the 
long term and determine whether TIVA is effective in 
the prevention of recurrence compared with volatile 
agents, including sevoflurane, desflurane, isoflurane, and 
enflurane. Our findings suggest that there are no significant 
differences between TIVA and balanced anesthesia with 
each volatile agent with regard to the prevention of long-
term recurrence. 
The concept that the perioperative environment 
affects the survival after cancer surgery was suggested 
40 years ago. It was reported that ether induced a greater 
secretion of stress hormones than halothane, reduced 
patient immunity, and therefore has negative effects on 
patient survival after surgery [11]. Although surgery is 
the most effective treatment for solid tumors, surgical 
manipulation leads to a risk of tumor spreading. Even 
after complete excision, the tumor cells released during 
surgery may eventually lead to recurrence if they bypass 
the immune system [12]. After complete excision, if 
the immune system is functioning normally, almost all 
the residual tumor cells are destroyed within 24 hours 
[13]. Unfortunately, perioperative immunosuppression 
inevitably starts early after surgery, and lasts for almost 
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Table 1: Comparison of characteristics between patients with breast cancer recurrence and those 
without breast cancer recurrence
No recurrence group 
(N = 2412)
Recurrence group 
(N = 233) P-value
Demographic data
Age (years) 50.1 (10.2) 48.9 (10.5) 0.072
BMI (kg/m2) 23.3 (3.1) 23.3 (2.9) 0.962
Comorbidity
HTN 478 (19.8) 44 (18.9) 0.796
DM 170 (7.1) 18 (7.7) 0.689
Cardiac disease 61 (2.5) 6 (2.6) > 0.999
Pulmonary disease 53 (2.2) 6 (2.6) 0.643
Endocrine disease 115 (4.8) 11 (4.7) > 0.999
Renal disease 18 (0.7) 1 (0.4) > 0.999
Liver disease 16 (0.7) 3 (1.3) 0.231
Neurological disease 41 (1.7) 4 (1.7) > 0.999
Others 22 (0.9) 2 (0.9) > 0.999
Anesthetic factors
Type of anesthetic agent 0.301
Sevoflurane 1480 (61.4) 133 (57.1)
Desflurane 606 (25.1) 58 (24.9)
Isoflurane 241 (10.0) 30 (12.9)
Enflurane 35 (1.5) 6 (2.6)
TIVA 50 (2.1) 6 (2.6)
Induction agents 0.253
Propofol 1850 (76.7) 187 (80.3)
Barbiturate 562 (23.3) 42 (19.7)
N2O 178 (7.4) 26 (11.2) 0.052
Muscle relaxants
Atracurium 95 (3.9) 12 (5.2) 0.382
Vecuronium 1 (0) 0 (0) > 0.999
Rocuronium 2318 (96.1) 221 (94.8) 0.379
Premedication* 1612 (66.8) 151 (64.8) 0.561
Antiemetic 2067 (85.7) 196 (84.1) 0.495
Rescue analgesics 2309 (95.7) 229 (98.3) 0.056
Hypertensive events 145 (6.0) 17 (7.3) 0.394
Hypotensive events 336 (13.9) 35 (15.0) 0.622
Colloid administration 39 (1.6) 4 (3.8) 0.788
RBC transfusion 10 (0.4) 2 (0.9) 0.286
Surgical factors
Surgery < 0.001
Breast-conserving 1194 (49.5) 63 (27.0)
Mastectomy 1218 (50.5) 170 (73.0)
Surgical duration (min) 207.2 (131.0) 212.5 (108.5) 0.487
TNM stage < 0.001
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1 1201 (49.8) 46 (19.7)
2 886 (36.7) 85 (36.5)
3 325 (13.5) 102 (43.8)
Receptors
Estrogen 1699 (70.4) 137 (58.8) < 0.001
Progesterone 1541 (63.9) 123 (52.8) 0.001
HER2 658 (27.3) 62 (26.6) 0.878
Histological analysis < 0.001
Well differentiated 539 (22.3) 20 (8.6)
Moderately differentiated 1063 (44.1) 110 (47.2)
Poorly differentiated 54 (22.6) 91 (39.1)
Others 266 (11.0) 12 (5.2)
Tumor types 0.311
IDC 2114 (87.6) 212 (91.0)
ILC 90 (3.7) 5 (2.1)
Others 208 (8.6) 16 (6.9)
Chemotherapy 1605 (66.5) 204 (87.6) < 0.001
Radiotherapy 1546 (64.1) 160 (68.7) 0.174
Data are presented as mean (standard deviation), or number (proportion, %).
BMI: body mass index, HTN: hypertension, DM: diabetes mellitus, TIVA: total intravenous anesthesia (with propofol), N2O: 
nitrous oxide, RBC: red blood cell, TNM: tumor–node–metastasis, HER2: human epidermal growth factor receptor 2, IDC: 
invasive ductal carcinoma, ILC: invasive lobular carcinoma 
Premedication*: Midazolam 0.03 mg kg-1 was administered. 
Figure 1: The survival probability for each anesthetic agent with regard to the recurrence after breast cancer surgery.
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7 days. This can allow tumor cells to escape from the 
immune system [14]. Cell-mediated immunity plays the 
predominant role in anti-tumor immunity, and involves 
natural killer cells and T lymphocytes. In the innate 
immune system, NK cells act as the first line of defense, 
while T lymphocytes activate the perioperative immune 
response as the secondary defence [15]. Although their 
effects are weaker than that of ether, isoflurane and 
halothane are known to decrease NK cell cytotoxicity 
[16]. Sevoflurane [17] and nitrous oxide [18] has also 
been reported to suppress tumor surveillance, including 
neutrophil chemotaxis. Moreover, interferon stimulates 
NK cell activity, an effect that is attenuated in the presence 
of halogenated anesthetics [16]. In addition, isoflurane 
has been found to increase hypoxia-inducible factor-
1a and its downstream effectors to promote survival in 
renal cell carcinoma [19]. For this reason, the role of the 
anesthetist in improving long-term outcomes after cancer 
surgery is gaining importance. Although controversial, 
increasing retrospective and preclinical data have 
implicated inhalational anesthesia and opioid analgesia as 
independent risk factors for disease recurrence, whereas 
loco-regional anesthesia and propofol-based TIVA have 
been considered to have potential chemo-preventative 
effects [20]. Prospective randomized controlled trials on 
this topic are ongoing. 
Table 2: Findings of univariate and multivariate Cox regression analyses for factors associated 
with the cancer recurrence after surgery for breast cancer
Parameters
Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Age (yr)
< 40 1(ref) 1 (ref)
40–50 0.682 0.475 0.980 0.038 0.79 0.548 1.138 0.206
50–60 0.724 0.495 1.057 0.094 0.771 0.527 1.129 0.182
60–70 0.674 0.426 1.064 0.091 0.763 0.481 1.21 0.250
> 70 0.572 0.258 1.269 0.170 0.7 0.306 1.603 0.399
BMI
< 18.5 1.039 0.526 2.053 0.912 0.845 0.427 1.674 0.630
18.5–23 1 (ref) 1 (ref)
23–25 1.027 0.740 1.425 0.875 1.104 0.794 1.534 0.557
25–30 1.053 0.764 1.450 0.753 1.008 0.731 1.39 0.961
> 30 0.850 0.374 1.936 0.699 0.774 0.338 1.774 0.545
Type of Anesthetic
agents
TIVA 1 (ref) 1 (ref)
Volatile agents 0.857 0.380 1.929 0.709 1.136 0.496 2.597 0.763
Antiemetic
No 1(ref) 1 (ref)
Yes 1.013 0.711 1.444 0.942 0.991 0.69 1.422 0.961
Rescue
Analgesics
No 1(ref) 1(ref)
Yes 1.805 0.578 5.639 0.310 1.361 0.429 4.311 0.601
Surgical procedure
BCS 1(ref) 1 (ref)
Mastectomy 2.533 1.897 3.383 < 0.001 1.888 1.397 2.552 < 0.001
TNM stage
1 1(ref) 1 (ref)
2 2.404 1.679 3.441 < 0.001 1.806 1.182 2.76 0.006
3 7.477 5.278 10.591 < 0.001 5.149 3.332 7.957 < 0.001
ER
Negative 1(ref) 1 (ref)
Positive 0.569 0.438 0.738 < 0.001 0.628 0.479 0.822 0.007
Chemotherapy
No 1 (ref) 1 (ref)
Yes 3.289 2.229 4.853 < 0.001 1.303 0.792 2.142 0.298
CI: confidence interval, OR: odds ratio, BMI: body mass index, TIVA: total intravenous anesthesia (with propofol), BCS: 
breast conserving surgery, TNM: tumor–node–metastasis, ER: estrogen receptor
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Propofol aids in the preservation of NK cell activity 
and increases cytotoxic T-cell activity, thus facilitating 
host resistance to recurrence and metastasis. Furthermore, 
it exhibits anti-inflammatory properties that could indicate 
greater host defense against disease recurrence in the 
perioperative period. These observations are supported 
by clinical findings [21]; therefore, the benefits of TIVA 
may be attributed to the facilitation of perioperative 
immune function. Propofol also has been found to 
inhibit hypoxia-inducible factors in prostate cancer 
[22], in accordance with the predominantly anti-cancer 
effects of TIVA reported in the literature. In preclinical 
studies, propofol inhibited cancer cell invasion [23], 
prevented metastasis [24], inhibited esophageal cancer 
proliferation and migration [25], and induced apoptosis 
in non-small cell lung cancer, colon cancer, and ovarian 
cancer cells [26]. Ke et al. [27] showed that combined 
propofol and remifentanil use in patients undergoing open 
cholecystectomy resulted in an increase in IL-10, an anti-
inflammatory cytokine, as opposed to the isoflurane. A 
retrospective analysis of breast, colon, and rectal cancer 
surgeries under TIVA or sevoflurane anesthesia found 
improved 1- and 5-year overall survival rates of 4.7% and 
5.6%, respectively [28]. 
Although volatile anesthetics are expected to 
adversely affect prognosis, including cancer recurrence, 
the evidence from in vitro studies regarding the potential 
deleterious effects of volatile agents is still conflicting. 
Moreover, there were no available data comparing the 
effects of TIVA and balanced anesthesia on long-term 
recurrence and survival. Thus, evidence to justify the 
avoidance of these agents in cancer patients is inadequate 
[19, 29, 30]. Our results suggest that there is no difference 
between TIVA and balanced anesthesia with each 
volatile agent with regard to the prevention of long-term 
recurrence and mortality in patients with breast cancer. 
However, as noted above, propofol tends to preserve 
immunity in comparison to sevoflurane or isoflurane in 
clinical trials as well as in animal studies. For this reason, 
we speculate that several factors account for the results 
of our study. First, not only propofol but also other many 
medications were administered during the perioperative 
Table 3: Association between anesthetic agents and postoperative cancer recurrence in patients 
with breast cancer after multivariate Cox regression analyses and propensity score matching
Parameters HR 95% CI P-value
Type of Anesthetic
agent
TIVA 1 (ref)
Sevoflurane 1.066 0.463 2.452 0.881
Desflurane 1.231 0.520 2.912 0.637
Isoflurane 1.330 0.544 3.256 0.532
Enflurane 1.451 0.459 4.594 0.526
1:5 matching
TIVA 1 (ref)
Sevoflurane 1.152 0.382 3.473 0.802
1:5 matching
TIVA 1 (ref)
Desflurane 1.233 0.314 4.839 0.764
1:5 matching
TIVA 1 (ref)
Isoflurane 1.829 0.306 10.946 0.508
1:5 matching
TIVA 1 (ref)
Enflurane - - - -
HR: hazard ratio, CI: confidence interval, TIVA: total intravenous anesthesia (with propofol)
*Multivariate Cox regression analyses were adjusted by age, body mass index (BMI), antiemetic, rescue analgesics, surgery 
type, tumor–node–metastasis (TNM) stage, estrogen receptor status, and chemotherapy use. The statistical significance of 
differences in the risk of recurrence between anesthetics was tested prior to matching, and the results demonstrated that, when 
propofol was used as a reference, the other anesthetics showed increased recurrence risk. However, the differences were not 
statistically significant. 
**For more sensitive and precise analysis, the relative risk of postoperative recurrence after breast cancer surgery was 
calculated after 1:5 propensity score matching after adjustment for age, BMI, hypertension, diabetic mellitus, cardiac disease, 
pulmonary disease, endocrinal disease, renal disease, liver disease, neurological disease, and TNM stage. The results showed 
no statistically significant differences between TIVA and volatile anesthetics. Because the frequency of enflurane use was 
low, event occurrence after matching did not meet the minimum number requirement. Therefore, its relative risk was not 
calculated.
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period. Furthermore, our retrospective study design 
did not permit accurate quantification of intraoperative 
remifentanil use, although it is considered that the total 
remifentanil dose infused during TIVA would be greater 
than that infused during inhalation anesthesia, and that 
the efficacy of propofol may have been offset by opioid 
usage. There is a strong suggestion from both retrospective 
clinical trials and experimental studies that opioids, 
which suppress immune function, may promote cancer 
progression and decrease long-term survival [31]. Most 
importantly, the effects of propofol on cancer recurrence 
may be relatively negligible compared with those of strong 
outcome predictors, such as the TNM stage. The reason for 
the reliability why our results can obtain reliability is that, 
previously known as predictors [31, 32], a higher TNM 
staging was found to be the strong surgical risk factor 
for breast cancer recurrence, and ER positivity has been 
shown to lower risk of recurrence in our study. Further, 
the previous animal and short-term follow-up immunity-
based clinical studies used a high concentration of volatile 
anesthetics alone for the induction and maintenance of 
anesthesia, which is no longer common clinical practice. 
On the other hand, the concentration of the volatile 
anesthetic agents analyzed in this study were set at more 
clinically relevant levels. Although this is a retrospective 
study, it is the first long-term follow-up clinical report to 
make such a comparison in breast cancer between TIVA 
and balanced anesthesia with volatile agents. Therefore, 
further prospective randomized clinical trials with long-
term follow-up should be conducted that analyses all 
variables, including opioid usage, to clarify the effects of 
TIVA during cancer surgery on postoperative recurrence 
and mortality.
There are several limitations in this study. First, 
as this is a retrospective study, the patients were not 
randomized and clinical care was not standardized. Thus, 
selection bias and the effects of unmeasured confounding 
variables cannot be excluded. Nevertheless, our data were 
supplemented, to some extent, by the retrospective study 
design, because all patients were perioperatively managed 
in a similar manner in the same hospital for 5 years. 
Furthermore, the method of anesthesia was relatively 
consistent. Second, although a large number of patients 
were analyzed, the number of patients who received 
TIVA was small (56/2645). However, we adjusted this 
factor by sensitivity analysis with propensity score 
matching, which revealed no differences between TIVA 
and balanced anesthesia with volatile agents with regard 
to postoperative breast cancer recurrence. 
In conclusion, our findings demonstrated that the 
type of general anesthesia, whether TIVA or balanced 
anesthesia with various volatile agents, has no association 
with the postoperative recurrence-free survival and 
overall survival in patients with breast cancer. However, 
anesthetic agents are administered at a point of potentially 
high vulnerability in terms of the dissemination and 
establishment of metastasis; therefore, there is a consistent 
need to determine the most appropriate anesthetic strategy 
for oncological surgeries in order to maximize long-term 
outcomes. 
Figure 2: The survival probability for each anesthetic agent with regard to postoperative overall survival in breast 
cancer patients.
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MATERIALS AND METHODS
The Institutional Review Board and Hospital 
Research Ethics Committee of Severance Hospital, 
Yonsei University Health System approved this study. 
The requirement for informed consent was waived by 
the institutional review board owing to the retrospective 
nature of the study. The medical records of all patients 
who underwent breast cancer surgery at the Breast Cancer 
Centre between November 2005 and December 2010 were 
retrospectively reviewed. The follow-up period ended in 
December 2015.
Anesthetic management 
Anesthesia was induced by bolus administration of 
propofol (1–2 mg kg−1) or pentothal sodium (4–5 mg kg−1) 
and remifentanil (1–2 μg kg−1). A neuromuscular blocking 
agent such as rocuronium, vecuronium, or atracurium was 
injected to facilitate tracheal intubation. Anesthesia was 
maintained by balanced anesthesia with volatile agents 
such as sevoflurane, desflurane, isoflurane, or enflurane 
with adjuvant intravenous infusion of remifentanil, 
or performed using TIVA with 2% propofol and 
remifentanil. Thirty minutes before surgery completion, 
fentanyl (1 μg kg−1) was injected for postoperative pain 
control. Antiemetic agents were selected as per the 
anesthesiologist’s preference. 
Clinico-pathological parameters
Clinico-pathological information, including the 
expression of ER, PR, and human epidermal growth factor 
receptor 2 (HER2), was obtained through medical records 
and the registry database. The registry database collected 
personal history, clinic-pathological parameters, treatment 
patterns, and follow-up outcomes associated with breast 
cancer. After definitive surgery for the breast and axilla, 
Table 4: Association between anesthetic agents and overall mortality in patients with breast cancer 
after multivariate Cox regression analyses and propensity score matching
Parameter HR 95% CI P-value
Type of Anesthetic
agent
TIVA 1 (ref)
Volatile agents 2.967 0.721 12.216 0.132
Type of Anesthetic
agent
TIVA 1 (ref)
Sevoflurane 2.748 0.664 11.369 0.163
Desflurane 3.277 0.777 13.834 0.106
Isoflurane 3.457 0.795 15.030 0.098
Enflurane 4.073 0.807 20.568 0.089
1:5 matching
TIVA 1 (ref)
Sevoflurane 2.848 0.357 22.713 0.323
1:5 matching
TIVA 1 (ref)
Desflurane 9.755 0.886 107.437 0.063
1:5 matching
TIVA 1 (ref)
Isoflurane - - - -
1:5 matching
TIVA 1 (ref)
Enflurane - - - -
HR: hazard ratio, CI: confidence interval, TIVA: total intravenous anesthesia (with propofol)
*Multivariate Cox regression analyses were adjusted by age, body mass index (BMI), antiemetic, rescue analgesics, surgery 
type, tumor–node–metastasis (TNM) stage, estrogen receptor status, and chemotherapy use. The statistical significance of 
differences in the postoperative mortality between anesthetics was tested prior to matching, and the results demonstrated that, 
when propofol was used as a reference, the other anesthetics showed increased overall mortality. However, the differences 
were not statistically significant. 
**For more sensitive and precise analysis, the relative risk of overall mortality after breast cancer surgery was calculated 
after applying 1:5 propensity score matching after adjustment for age, body mass index, hypertension, diabetic mellitus, 
cardiac disease, pulmonary disease, endocrinal disease, renal disease, liver disease, neurological disease, and tumor–node–
metastasis stage. The results showed no statistically significant differences between TIVA and the other anesthetics. Because 
the frequency of enflurane and isoflurane use was low, event occurrence after matching did not meet the minimum number 
requirement. Therefore, the relative risks were not calculated.  
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adjuvant treatments were administered according to the 
patients’ tolerance levels. Clinical follow-up assessments 
included history-taking, physical examination, laboratory 
tests, and imaging every 6–12 months for relapse 
detection. The TNM stage was determined using the 
American Joint Committee on Cancer 7th edition 
criteria. Tumors with ≥ 1% cells with nuclear staining 
were considered positive for ER and PR, according to 
the American Society of Clinical Oncology/College of 
American Pathologists (ASCO/CAP) guidelines [33]. 
Loco-regional recurrence was defined as tumor recurrence 
in the ipsilateral breast, chest wall, and regional lymph 
nodes. Any recurrence at a distant site, including the 
contralateral axillary or supraclavicular lymph nodes, 
was considered distant metastasis. Cancer recurrence was 
evaluated from the date of the first curative surgery to the 
date of the first loco-regional or distant recurrence. Overall 
survival was calculated from the date of the first surgery 
to the date of the last follow-up or death from any cause.
Data collection
Our primary outcome was the effect of anesthetic 
agents on postoperative breast cancer recurrence. We 
collected baseline demographic data, including age, 
body mass index, and comorbidities, and anesthetic data, 
including induction agents, maintenance anesthetics, 
muscle relaxants, and usage of antiemetic and rescue 
analgesics, among others. We also documented surgical 
data, including the surgery type, surgical duration, TNM 
stage, receptor status, histological type, tumor type, and 
chemotherapy or radiotherapy use.
Statistical analysis
Patients with and without breast cancer recurrence 
were compared for potential confounders using the x2 
test for categorical variables and the t-test for continuous 
variables. Continuous data such as age and body mass 
index (BMI) were categorized by drawing a smooth 
hazard ratio curve because there was no linear relationship 
with breast cancer recurrence. To identify the association 
between independent variables and the primary endpoint, 
we used a multidimensional approach. The univariate 
association between recurrence-free survival (and overall 
survival) and anesthetic agents was assessed using 
the Kaplan–Meier survival estimate, and the different 
anesthetic groups were compared using the log-rank 
test. Univariate and multivariate associations between 
postoperative breast cancer recurrence and all potential 
baseline confounders were assessed using Cox proportional 
hazards regression. First, univariate regression analysis 
was performed to identify significant risk factors for 
recurrence. Then, variables with a P-value of < 0.1 were 
included in a multivariate regression analysis. Hazard ratios 
(HRs) and associated 95% confidence intervals (CIs) were 
estimated. Potential confounders for analysis were selected 
according to the literature. We also performed sensitivity 
analysis for our chosen method (multivariate modelling) 
to assess the robustness of our findings regarding the 
association between the anesthetic agents and recurrence 
(and mortality), wherein we adjusted for confounding using 
propensity score matching. An independent t-test or a x2 
test, with a significance level of 0.05, was performed to 
identify variables causing statistical differences between 
TIVA and volatile anesthetics. The variables used for 
matching were age, BMI, hypertension, diabetic mellitus, 
cardiac disease, pulmonary disease, endocrinal disease, 
renal disease, liver disease, neurological disease, and 
tumor–node–metastasis stage, and the propensity score 
was calculated using logistic regression analysis. A 
greedy heuristic approach was used to find the optimally 
matching group without any loss due to statistical power 
or matching. The greedy heuristic approach involves a 
method where cases with differences exceeding twice the 
standard deviation (SD) during the process of matching 
similar propensity scores are not matched. Accordingly, 
1:5 matching was found to be the most effective. The 
P-value of < 0.05 was considered statistically significant. 
All statistical analyses were performed with SAS version 
9.4 (SAS Institute Inc., Cary, NC, USA), and Kaplan–
Meier curves were analyzed using R-package version 3.0.2 
(www.r-project.org).
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